These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19880429)

  • 1. The effect of the tachykinin NK(2) receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in asthmatics.
    Schelfhout V; Van De Velde V; Maggi C; Pauwels R; Joos G
    Ther Adv Respir Dis; 2009 Oct; 3(5):219-26. PubMed ID: 19880429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics.
    Joos GF; Van Schoor J; Kips JC; Pauwels RA
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1781-4. PubMed ID: 8665034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma.
    Schelfhout V; Louis R; Lenz W; Heyrman R; Pauwels R; Joos G
    Pulm Pharmacol Ther; 2006; 19(6):413-8. PubMed ID: 16364669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics.
    Van Schoor J; Joos GF; Chasson BL; Brouard RJ; Pauwels RA
    Eur Respir J; 1998 Jul; 12(1):17-23. PubMed ID: 9701408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma.
    Boot JD; de Haas S; Tarasevych S; Roy C; Wang L; Amin D; Cohen J; Sterk PJ; Miller B; Paccaly A; Burggraaf J; Cohen AF; Diamant Z
    Am J Respir Crit Care Med; 2007 Mar; 175(5):450-7. PubMed ID: 17170385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.
    Norris V; Choong L; Tran D; Corden Z; Boyce M; Arshad H; Holgate S; O'Connor B; Millet S; Miller B; Rohatagi S; Kirkesseli S
    J Allergy Clin Immunol; 2005 Oct; 116(4):761-7. PubMed ID: 16210048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
    J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: a randomized, placebo-controlled, double-blind, crossover study.
    Langley SJ; Allen D; McDonnell B; Wheeler N; Sharma RK; Sykes A; Woodcock A
    Clin Ther; 2005 Jul; 27(7):1004-12. PubMed ID: 16154479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction.
    Raissy HH; Harkins M; Esparham A; Kelly HW
    Pharmacotherapy; 2007 Sep; 27(9):1231-6. PubMed ID: 17723076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction.
    Schelfhout V; Van De Velde V; Pauwels R; Joos G
    Pulm Pharmacol Ther; 2008; 21(2):276-84. PubMed ID: 17611132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nepadutant Menarini Richerche.
    Ahluwalia A
    Curr Opin Investig Drugs; 2001 Jul; 2(7):919-22. PubMed ID: 11757791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models.
    Lecci A; Carini F; Tramontana M; D'Aranno V; Marinoni E; Crea A; Bueno L; Fioramonti J; Criscuoli M; Giuliani S; Maggi CA
    J Pharmacol Exp Ther; 2001 Oct; 299(1):247-54. PubMed ID: 11561086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients.
    Joos GF; Vincken W; Louis R; Schelfhout VJ; Wang JH; Shaw MJ; Cioppa GD; Pauwels RA
    Eur Respir J; 2004 Jan; 23(1):76-81. PubMed ID: 14738235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
    Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
    Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a tachykinin NK(2) receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs.
    Giuliani S; Guelfi M; Toulouse M; Buéno L; Lecci A; Tramontana M; Criscuoli M; Maggi CA
    Eur J Pharmacol; 2001 Mar; 415(1):61-71. PubMed ID: 11245853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.
    De Lepeleire I; Reiss TF; Rochette F; Botto A; Zhang J; Kundu S; Decramer M
    Clin Pharmacol Ther; 1997 Jan; 61(1):83-92. PubMed ID: 9024176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nepadutant, a neurokinin 2 tachykinin receptor antagonist, on immediate-early gene expression after trinitrobenzenesulfonic acid-induced colitis in the rat.
    Birder LA; Kiss S; de Groat WC; Lecci A; Maggi CA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):272-6. PubMed ID: 12490601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.